Surufatinib plus toripalimab and chemotherapy for second-line treatment of RAS/BRAF mutant (MT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC): A single-arm, phase II study (APHRODITE)

被引：0
|
作者：
Zhang, H. [1 ]
Liu, L. [1 ]
Zhu, X. [1 ]
Gao, Y. [1 ]
Tong, Z. [1 ]
Fu, Q. [1 ]
Bao, X. [1 ]
Dai, X. [1 ]
Zhao, P. [1 ]
Fang, W. [1 ]
Zheng, Y. [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Oncol Dept, Sch Med, Hangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
41P
引用
收藏
页码：S21 / S21
页数：1
相关论文
共 50 条
  • [21] Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Lee, Michael Sangmin
    Loehrer, Patrick J.
    Imanirad, Iman
    Cohen, Stacey
    Ciombor, Kristen Keon
    Moore, Dominic T.
    Carlson, Cheryl Ann
    Sanoff, Hanna Kelly
    McRee, Autumn Jackson
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [22] Results of a phase II study evaluating trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
    Patel, Manish R.
    Falchook, Gerald Steven
    Hamada, Kensuke
    Makris, Lukas
    Winkler, Robert E.
    Gordon, Gilad Shalag
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [23] Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study
    Cheng, Yu
    Teng, Zan
    Zhang, Yanqiao
    Jin, Bo
    Zheng, Zhendong
    Man, Li
    Wang, Zhenghua
    Teng, Yuee
    Yu, Ping
    Shi, Jing
    Luo, Ying
    Wang, Ying
    Zhang, Jingdong
    Zhang, Huijuan
    Liu, Jiwei
    Chen, Hao
    Xiao, Jiawen
    Zhao, Lei
    Zhang, Lingyun
    Jiang, Yu
    Chen, Ying
    Zhang, Jian
    Wang, Chang
    Liu, Sa
    Qu, Jinglei
    Qu, Xiujuan
    Liu, Yunpeng
    BMC CANCER, 2024, 24 (01)
  • [24] Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study
    Hao, Chunyi
    Du, Chengyou
    Peng, Baogang
    Zhang, Wu
    Shan, Yunfeng
    Lv, Ang
    Wu, Jianhui
    Shang, Changzhen
    Luo, Xuan
    Wei, Jinxing
    Xiao, Heng
    Qiu, Jianguo
    Hua, Yunpeng
    Shen, Shunli
    Wang, Ting
    Dai, Shengjie
    Chen, Xiang
    Yan, Shican
    Hao, Chunyi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [25] An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer
    Cohn, Allen L.
    Shumaker, Grace C.
    Khandelwal, Pankaj
    Smith, David A.
    Neubauer, Marcus A.
    Mehta, Nilesh
    Richards, Donald
    Watkins, David L.
    Zhang, Kathy
    Yassine, Mohamed R.
    CLINICAL COLORECTAL CANCER, 2011, 10 (03) : 171 - 177
  • [26] Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial
    Li, Sheng
    Li, Xiaoyou
    Zhu, Qianni
    Gao, Jin
    Zhu, Chunrong
    Zhu, Liangjun
    CANCER CONTROL, 2024, 31
  • [27] Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): An academic, multicenter, single-arm, two-stage, phase 2 study
    Cardone, C.
    Piccirillo, M.
    Rosati, G.
    De Stefano, A.
    Romano, C.
    Nappi, A.
    Zanaletti, N.
    Foschini, F.
    Cassata, A.
    Casaretti, R.
    Silvestro, L.
    Tatangelo, F.
    Lastoria, S.
    Raddi, M.
    Bilancia, D.
    Febbraro, A.
    Martinelli, E.
    Ciardiello, F.
    Delrio, P.
    Perrone, F.
    Budillon, A.
    Avallone, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S271 - S271
  • [28] Gemcitabine plus nab-paclitaxel for second-line therapy of pancreatic cancer: A phase II, single-arm, multicenter study
    Huh, Gunn
    Choi, Jin Ho
    Lee, Sang Hyub
    Chun, Jung Won
    Cho, In Rae
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Lee, Hee Seung
    Bang, Seungmin
    ANNALS OF ONCOLOGY, 2021, 32 : S287 - S287
  • [29] Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial
    Wang, Qin
    Tong, Fan
    Qiao, Li
    Qi, Liang
    Sun, Yi
    Zhu, Yahui
    Ni, Jiayao
    Liu, Juan
    Kong, Weiwei
    Liu, Baorui
    Du, Juan
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (10)
  • [30] Capecitabine (XE) plus irinotecan (IRI) as second-line treatment (XELIRI) for metastatic colorectal cancer (MCRC): Feasibility and safety results from a phase II study
    Fiorentini, G.
    Cantore, M.
    Dentico, P.
    Pacetti, P.
    Rossi, S.
    Della Seta, R.
    Bernardeschi, P.
    De Giorgi, U.
    Turrisi, G.
    ANNALS OF ONCOLOGY, 2005, 16 : 42 - 42
12345